![]() |
市場調査レポート
商品コード
1472990
研究用抗体および試薬市場の評価:製品・技術・用途・エンドユーザー・地域別の機会および予測 (2017-2031年)Research Antibodies and Reagents Market Assessment, By Product, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
||||||
カスタマイズ可能
|
研究用抗体および試薬市場の評価:製品・技術・用途・エンドユーザー・地域別の機会および予測 (2017-2031年) |
出版日: 2024年05月01日
発行: Market Xcel - Markets and Data
ページ情報: 英文 229 Pages
納期: 3~5営業日
|
世界の研究用抗体および試薬の市場規模は、2023年の126億3,000万米ドルから、2024年から2031年の予測期間中は7.08%のCAGRで推移し、2031年には218億2,000万米ドルの規模に成長すると予測されています。
世界の研究用抗体および試薬市場の発展は、慢性疾患や感染症の増加、細胞・遺伝子治療市場の拡大、技術の進歩、政府やその他の関連産業によるR&D活動への投資の増加など、さまざまな要因によって推進されています。さらに、複数の大手企業の存在、共同事業、バイオ医薬品・バイオテクノロジー産業への関心の高まりが、世界の研究用抗体および試薬市場の成長を加速させています。
抗体および試薬は、自己免疫疾患、癌、感染症などさまざまな慢性疾患の診断と治療に広く使用されています。このため、抗体および試薬市場では研究用途の需要が増加しています。AIの応用などの技術の進歩により、研究者は抗体や試薬の試験や検証の質を向上させることができます。バイオ医薬品業界や医薬品開発業界などのライフサイエンス業界の発展、政府や関連業界による投資や資金調達の増加が市場成長の要因となっています。さらに、M&Aやパートナーシップ契約など、頻繁かつ継続的な共同研究活動が、この市場での研究を促進し、世界の研究用抗体および試薬市場をさらに押し上げています。
慢性疾患の有病率の増加:
研究用抗体および試薬の需要は、慢性疾患の有病率の上昇により大幅に増加しています。高齢化人口の増加は、感染症、心血管疾患、癌、自己免疫疾患など、いくつかの慢性的な健康状態の発症の原因となっています。これらの慢性疾患は、診断法や革新的な治療法をもたらすための継続的なR&D活動を必要としています。WHOの2023年の統計によると、慢性疾患は世界中の人々が罹患するもっとも一般的な疾患であり、世界中で毎年4,100万人が死亡しています。座りっぱなしのライフスタイル、不健康な食事、肥満、タバコやアルコールの過剰摂取は、人口の慢性疾患有病率上昇の主要な危険因子です。慢性疾患に対する有効な治療法が十分に確立されていないため、効果的で効率的な医薬品や革新的な診断法・治療法の実現が重視されるようになり、その結果、抗体および試薬産業における高度な研究の必要性が高まっています。これらすべての要因により、世界の研究用抗体および試薬市場は活況を呈しています。
技術的進歩:
研究用抗体および試薬の技術は急速に進化しており、市場の著しい成長をもたらしています。CRISPR-Cas9やシングルセル解析の開発などの技術的進歩が需要を増大させており、いくつかの大手企業はこの業界の進歩と成長を加速させるために革新的な製品の発売を開発しています。例えば、バイオテクノロジー大手Cytek Biosciences, Inc.は2023年12月、試薬カクテル調製システムCytek Orionを発表しました。このシステムは、試薬カクテルの調製を全自動化する革新的な技術で、研究室のワークフローを簡素化し、満足のいく結果をもたらし、精度を高め、生産工程をスピードアップします。
当レポートでは、世界の研究用抗体および試薬の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。
Global research antibodies and reagents market is projected to witness a CAGR of 7.08% during the forecast period 2024-2031F, growing from USD 12.63 billion in 2023 to USD 21.82 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.
Growth in the global research antibodies and reagents market is driven by various factors, such as the increasing prevalence of chronic diseases and infectious diseases, the growing cell and gene therapy market, technological advancements, and increased investments by the government and other related industries to conduct research and development activities. Moreover, the presence of several leading players, collaborative ventures, and growing interest in the biopharmaceutical and biotechnological industry accelerates the global research antibodies and reagents market growth.
Antibodies and reagents are widely used to diagnose and treat various chronic diseases, such as autoimmune diseases, cancers, and infections. Due to this, there is increased demand for research in the antibodies and reagents market. Technological advancements such as the application of artificial intelligence (AI) enable researchers to improve the quality of antibodies and reagents testing and validation. Growth in the life science industry, such as the biopharmaceutical and drug development industries, along with increased investments and funding by the government and related industries, are the factors leading to market growth. Moreover, frequent and consistent collaboration activities such as mergers and acquisitions and partnership agreements to increase research in this market further propel the global research antibodies and reagents market.
Increasing Prevalence of Chronic Diseases
The demand for research in antibodies and reagents is increasing significantly due to the rising prevalence of chronic diseases. The increasing aging population is responsible for the onset of several chronic health conditions such as infections, cardiovascular diseases, cancer, and autoimmune diseases. These fatal chronic diseases need continuous research and development activities to bring diagnostics measures and innovative therapeutics. According to WHO 2023 statistics, chronic diseases are the most common diseases affecting people from all over the world and are responsible for 41 million deaths every year worldwide. A sedentary lifestyle, unhealthy diet, obesity, and excessive tobacco and alcohol consumption are the leading risk factors for the rising prevalence of chronic diseases among the population. The insufficient availability of successful therapies for chronic illnesses has increased emphasis on bringing effective and efficient pharmaceuticals and innovative diagnostics and treatments, consequently increasing the necessity for conducting advanced research in the antibodies and reagents industry. Due to all these factors, the global research antibodies and reagents market is flourishing.
Technological Advancements
Technological advancements in research antibodies and reagents are rapidly evolving, leading to tremendous growth in the research antibodies and reagents market. Technological advancements such as the development of CRISPR-Cas9 and single-cell analysis are increasing the demand, due to which several leading players are developing innovative product launches to accelerate advancements and growth in this industry. For instance, in December 2023 Cytek Biosciences, Inc., a leading biotechnology company, announced its latest launch "Cytek Orion", which is a reagent cocktail preparation system. It is an innovative fully automated reagent cocktailing technology that eases the laboratory workflow, leading to satisfactory results, enhancing accuracy, and speeding up the production process. This new system can mix and manage cocktail mixtures consisting of as many as 60 distinct reagent antibody conjugates. Due to these innovations and advancements, the global research antibodies and reagents market is expected to flourish in the forecasted period.
Immunohistochemistry Holds a Significant Market Share
Based on technology, immunohistochemistry holds a significant market share as it is the most preferred diagnostic test for diseases such as cancer and it is estimated that its use is significantly increasing with the increasing demand for personalized medicine. Frequent antibodies and reagents launched by the leading biopharmaceutical companies to accelerate application in immunohistochemistry technologies are leading to the faster growth of this technology. For instance, in March 2023, Aptamer Group plc, a leading provider of custom optimer selection and development services, announced the launch of a new reagent known as "Optimer-Fc", for application in automated immunohistochemistry (IHC) workflows. These innovative and potential product launches by key market players are accelerating the market growth.
Increased Application in Proteomics
Based on application, proteomics holds the maximum market share due to its technological advancements and potential in preparing personalized medicines. Due to its higher demand in the industry, several leading players are launching innovative products in this segment. For instance, in July 2023, Alfa Chemistry, a well-known chemical supplier, announced the launch of various proteomics products that will enhance life science research in the healthcare industry. These high-quality proteomics products, including staining reagents, western substrate, and TMB ELISA substrates are extensively used in protein analysis. These frequent product launches lead to escalating research activities in proteomics contributing to the overall market growth.
Asia-Pacific is Expected to be the Fastest-growing Region
Asia-Pacific is expected to be the fastest-growing region in the global research antibodies and reagents market. The rapidly increasing population and prevalence of chronic and infectious diseases in this region are accelerating the demand for increased research and development activities in developing efficient antibodies and reagents to improve drug discovery and enhance medical facilities. Asia-Pacific is an emerging market that has huge potential in the life science industry, due to which key market players are continuously developing partnership collaborations and establishing research institutes in this region to enhance research and development in this market. For instance, in September 2023, Agilent Technologies Inc. announced that it would partner with Advanced Cell Therapy and Research Institute in Singapore for three years. This partnership aims to bring innovation and advancement and enhance research studies in the field of cell and gene therapy. These collaborations within the Asia-Pacific are flourishing in the research antibodies and reagents market in this region.
Future Market Scenario (2024-2031F)
The global research antibodies and reagents market is expected to grow due to several factors. The increasing prevalence of chronic diseases worldwide is accelerating the demand for extensive research activities in the antibodies and reagents market to bring innovation and advancement in the healthcare sector. Technological advancements, such as the application of AI to ease the research process in this market, along with increased investments and funds by the government and life science industry are leading to escalating growth. Additionally, frequent collaboration activities such as partnerships to enhance research studies in this market are expected to flourish the global research antibodies and reagents market in the forecast period.
For instance, in February 2023, Bio-Techne Corporation and Cell Signaling Technology, both life science companies announced the partnership to add Simple Western validation to CST antibodies. This approach will enable researchers from different disciplines to study the molecular signaling pathways easily by using this simple Western validation platform.
Middle East and Africa
Key Players Landscape and Outlook
In the research antibodies and reagents market, several companies and research institutes, operating in antibodies and reagents research and development activities are continuously involved in collaboration activities such as developing strategic partnerships and establishing new research centers. These collaboration ventures play a crucial role in propelling the global research antibodies and reagents market's growth and expansion. These partnerships enable companies to gain informative insights regarding the latest and innovative research tools and methodology, access each other's knowledge, resources, markets, and technologies, and enhance research and development activities to bring advancement in antibodies and reagents developments. These collaborative ventures lead to innovation, expedite product development, and contribute to the enduring and robust growth of the global market.
For instance, in August 2023, Danaher Corporation, a global leader in science and technology, announced the acquisition of Abcam plc, which is a global supplier of protein consumables. This strategic acquisition will accelerate life science research and development activities to enhance diagnostics and treatment of complex diseases and propel the drug discovery process. These frequent collaborative ventures further assist in elevating the global research antibodies and reagents market.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.